US FDA approves Zevra's treatment for rare genetic disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Zevra Therapeutics, Inc. (ZVRA) PT Raised to $21 at Roth/MKM
September 24, 2024 5:40 AM EDTRoth/MKM analyst Jonathan Aschoff raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $21.00 (from $19.00) while maintaining a Buy rating.
The analyst comments "The FDA approved MIPLYFFA for NPC. As ZVRA needs about eight to 12 weeks to make the drug commercially... More
